In this скачать в хорошем качестве

In this

In this #DocTalk from Feb 10, 2022, Dr. Kopetz discusses ctDNA testing for Minimal Residual Disease with Dr. Manju George, the Scientific Director at Paltown. 00:48: Overview of the talk 1:17: Minimal Residual Disease in CRC possible how? 2:38: CTCs versus ctDNA 3:00: Different kinds of ctDNA tests 3:43: Why are ctDNA MRD tests exciting? 4:45: What is minimal residual disease (MRD)? 6:30: CtDNA status post surgery 8:30: Single test versus serial tests 9:28: Different scenarios post-treatment 10:26: Currently available tests 11:08: CIRCULATE-Japan results 13:50: DFS by CtDNA dynamics 14:47: CtDNA clearance after adj chemo 15:43: Clinical utility of ctDNA MRD testing 16:40: COBRA Stage II colon cancer ctDNA trial 16:50: CIRCULATE US trial for early stage III colon cancer 19:08: DYNAMIC-III trial 20:06: Clinical Utility: trials for new curative intent treatments 22:27: BioNTech personalized vaccine trial for ctDNA+ patients 24:19: CtDNA MRD testing allows new kinds of trial design 26:32: Proof of principle MRD pilot trials 28:25: Resources for people interested 29:03: INTERCEPT Program at MDA 29:46: FAQ: How to interpret test results? 32:40: FAQ: Quick primer on survival curves 35:15: FAQ: Interval between ctDNA positivity & results on imaging 36:30: FAQ: Can a ctDNA+ status change without treatment? 37:43: FAQ: What does negative ctDNA test status over time mean? 38:50: FAQ: Can the ctDNA+ test tell where the cancer is hiding? 39:37: FAQ: I’m ctDNA+, should I start the next line treatment now? 42:10: FAQ: Is ctDNA MRD testing useful with resected peritoneal disease? 44:28: Conclusions 46:55-59:05 Q&A For #DocTalks on many CRC-relevant topics, please visit The Lecture Hall at COLONTOWN University here https://learn.colontown.org/learningc...